| Name | Liothyronine |
| Description | Liothyronine (Tresitope) is a synthetic and highly active thyroid hormone that acts as an effective agonist of TRα and TRβ (Ki = 2.33 nM for both hTRα and hTRβ). It activates the TRβ1 receptor, promotes the metabolism of carbohydrates, proteins, and fats, accelerates the oxidative processes in tissue cells, maintains basal metabolic rate, and supports normal growth and development. Liothyronine can be used to induce hyperthyroidism models. |
| In vitro | METHODS: Mouse colon adenocarcinoma cells MC38 were treated with Liothyronine (12.5-100 µM) for 24-72 h. Cell viability was measured using MTT Assay.
RESULTS: Liothyronine did not affect the cell viability of MC38 cells at the concentrations tested. [1]
METHODS: Jurkat hTIGIT cells were stimulated with anti-CD3 and anti-CD28 stimulatory antibodies and treated with anti-TIGIT (1 µg/mL) and Liothyronine (100 µM) for 48 h. The frequency of IL-2 secreting Jurkat hTIGIT was detected using Flow cytometry.
RESULTS: TIGIT/PVR interaction significantly inhibited IL-2 secretion from Jurkat hTIGIT cells, and the inhibition was significantly reversed by a functional anti-TIGIT antibody and Liothyronine, which has the typical characteristics of an immune checkpoint blocker. [1] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, Liothyronine (1.5-5 mg/kg, normal saline with 3% DMSO and 0.5% Tween-80) was injected intraperitoneally every two days for two weeks into C57BL/6 mice bearing MC38 tumors.
RESULTS: Both low and high doses of Liothyronine significantly inhibited the growth of MC38 tumors. Liothyronine significantly increased the frequency of tumor-infiltrating CD8+ T cells and significantly enhanced the secretion of IFN-γ by tumor-infiltrating CD4+ T cells treated with high doses of Liothyronine. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4.95 mg/mL (7.6 mM), Solution.
DMSO : 3.25 mg/mL (4.99 mM), Sonication is recommended.
|
| Keywords | TRβ | TRα | Thyroidhormonereceptor(THR) | Thyroidhormonereceptor | Thyroid hormone receptor(THR) | Thyroid hormone receptor | thyroid hormone | THR | T-3 | T 3 | EndogenousMetabolite | Endogenous Metabolite |
| Inhibitors Related | Sucrose | Aceglutamide | Nicotinamide riboside malate | DL-Lysine | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Malic acid | Formamide | Glycerol | Thymidine | Corn starch | Gluconate Calcium |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Nuclear Receptor Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Human Endogenous Metabolite Library | Bioactive Compounds Library Max | Mouse Metabolite Compound Library | Human Metabolite Library | NMPA-Approved Drug Library |
United States
